George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.40
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.20 (14.286%)
Open: 1.50
High: 1.50
Low: 1.50
Prev. Close: 1.50
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Jan 2018 15:52

RNS Number : 1812C
Physiomics PLC
17 January 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

PHYSIOMICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Jason Cropper

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

15 January 2018

6. Date on which issuer notified (DD/MM/YYYY):

15 January 2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.4%

58,785,394

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

2,000,000

3.4%

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Preston

Date of completion

15 January 2018

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEDLFFVFFEBBF
Date   Source Headline
24th Jun 20137:00 amRNSWins Poster Award
20th Jun 20134:28 pmRNSAward of Grant
11th Jun 20137:00 amRNSPopulation Approach Group Europe
6th Jun 20137:00 amRNSVirtual Tumour Clinical Contract
8th Apr 20138:03 amRNSPhysiomics to present new developments
25th Mar 20137:00 amRNSPhysiomics to provide cardiac toxicity modelling
18th Mar 20137:00 amRNSNew clinical PK/PD modelling service
13th Feb 201311:10 amRNSIssue of Options
11th Feb 20133:23 pmRNSDirector Declaration
8th Feb 20137:00 amRNSHalf Yearly Report
22nd Jan 20137:00 amRNSSEDA Arrangement
7th Jan 20137:00 amRNSRecruitment of Senior Scientist with Clinical PK/P
18th Dec 20129:46 amRNSFrench R&D Tax Credit Accreditation
17th Dec 201212:29 pmRNSResult of AGM
14th Nov 20127:00 amRNSFinal Results for the year ended 30 June 2012
8th Oct 20128:38 amRNSNew US Business Development Consultant
10th Aug 20127:53 amRNSNew Agreement to optimise oncology combination
7th Aug 20123:57 pmRNSStmnt re Share Price Movement
4th Jul 20123:25 pmRNSTrading Update
7th Jun 201211:42 amRNSPresentation at the 2012 PAGE 21st Annual Meeting
29th May 201212:37 pmRNSShare Price Movement
21st May 201212:03 pmRNSDirector/PDMR Shareholding
30th Apr 20127:00 amRNSTotal Voting Rights
26th Apr 20128:49 amRNSIssue of Equity
29th Mar 20127:00 amRNSParticipation in AACR Annual Meeting 2012
16th Mar 20127:00 amRNSPhysiomics to present at the Bio-Europe Conference
7th Mar 20127:00 amRNSHalf Yearly Report
1st Mar 20127:20 amRNSNew Agreement with Global Pharma Company
31st Jan 201211:57 amRNSPhysiomics to enter new therapeutic area
20th Dec 201112:05 pmRNSIssue of Options
18th Nov 201110:07 amRNSResult of AGM
9th Nov 20115:01 pmRNSIssue of Options
2nd Nov 20117:00 amRNSExecution of New Agreement
19th Oct 20117:00 amRNSScientific Board Update
11th Oct 20118:39 amRNSFinal Results
29th Sep 201110:17 amRNSJoint servs alliance executed with Jubilant Biosys
27th May 201110:33 amRNSIssue of Equity
13th May 20114:34 pmRNSIssue of Equity
4th May 20117:00 amRNSNew collaboration with Pharmacometrics Limited
28th Apr 20119:46 amRNSTotal Voting Rights
6th Apr 20117:00 amRNSIssue of Equity
5th Apr 20117:00 amRNSUpcoming Presentation
1st Apr 201110:32 amRNSResults Update
29th Mar 20111:10 pmRNSIssue of Equity
9th Mar 20117:00 amRNSHalf Yearly Report
8th Mar 20117:00 amRNSUpdate: Joint services alliance w. Jubilant Biosys
15th Feb 20114:56 pmRNSStmnt re Share Price Movement
9th Feb 20119:25 amRNSStmnt re Share Price Movement
8th Feb 201111:47 amRNSStmnt re Share Price Movement
7th Feb 20119:42 amRNSIssue of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.